Tellus Therapeutics is a neonatal care company developing safe and effective interventions for unmet needs of newborns. Founded in October 2018, Tellus is translating breakthrough science licensed from Duke University that originated in board-certified neonatologist Dr. Eric Benner's research laboratory together with collaborator and Tellus scientific co-founder Dr. Simon Gregory. Dr. Benner's work identified compounds in breast milk that induce the regeneration of myelin-producing oligodendrocytes and repair WMI in animal models of perinatal brain injury. Tellus's goal for its lead asset, TT-20, is to provide a treatment for every baby born at risk for brain injury and to improve neurodevelopmental outcomes for affected children.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/13/22 | $35,000,000 | Series A |
Perceptive Xontogeny Venture Fund | undisclosed |
